82 related articles for article (PubMed ID: 28376677)
1. Lens opacities in children using methylphenidate hydrochloride.
Duman NS; Duman R; Sarı Gökten E; Duman R
Cutan Ocul Toxicol; 2017 Dec; 36(4):362-365. PubMed ID: 28376677
[TBL] [Abstract][Full Text] [Related]
2. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
[TBL] [Abstract][Full Text] [Related]
3. Methylphenidate (Ritalin)-associated cataract and glaucoma.
Lu CK; Kuang TM; Chou JC
J Chin Med Assoc; 2006 Dec; 69(12):589-90. PubMed ID: 17182354
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
[TBL] [Abstract][Full Text] [Related]
6. The effects of methylphenidate on refraction and anterior segment parameters in children with attention deficit hyperactivity disorder.
Larrañaga-Fragoso P; Noval S; Rivero JC; Boto-de-los-Bueis A
J AAPOS; 2015 Aug; 19(4):322-6. PubMed ID: 26235791
[TBL] [Abstract][Full Text] [Related]
7. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
Walitza S; Kämpf K; Artamonov N; Romanos M; Gnana Oli R; Wirth S; Warnke A; Gerlach M; Stopper H
Toxicol Lett; 2009 Jan; 184(1):38-43. PubMed ID: 19015014
[TBL] [Abstract][Full Text] [Related]
8. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
Ince Tasdelen B; Karakaya E; Oztop DB
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
[TBL] [Abstract][Full Text] [Related]
9. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
10. A post hoc analysis of d-threo-methylphenidate hydrochloride (focalin) versus d,l-threo-methylphenidate hydrochloride (ritalin).
Weiss M; Wasdell M; Patin J
J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1415-21. PubMed ID: 15502601
[TBL] [Abstract][Full Text] [Related]
11. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
[TBL] [Abstract][Full Text] [Related]
12. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
[TBL] [Abstract][Full Text] [Related]
13. Methylphenidate treatment and dyskinesia in children with attention-deficit/hyperactivity disorder.
Balázs J; Dallos G; Keresztény A; Czobor P; Gádoros J
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):133-8. PubMed ID: 21486166
[TBL] [Abstract][Full Text] [Related]
14. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
[TBL] [Abstract][Full Text] [Related]
15. Association Between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder.
Park SY; Kim EJ; Cheon KA
J Child Adolesc Psychopharmacol; 2015 Oct; 25(8):633-40. PubMed ID: 26402385
[TBL] [Abstract][Full Text] [Related]
16. [Influence of methylphenidate on growth of school age children with attention deficit hyperactivity disorder].
Zhang HY; Du ML; Zhuang SQ; Liu MN
Zhonghua Er Ke Za Zhi; 2005 Oct; 43(10):723-7. PubMed ID: 16255846
[TBL] [Abstract][Full Text] [Related]
17. Weight, Height, and Body Mass Index in Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate.
Díez-Suárez A; Vallejo-Valdivielso M; Marín-Méndez JJ; de Castro-Manglano P; Soutullo CA
J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):723-730. PubMed ID: 28817309
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health.
Moungnoi P; Maipang P
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S158-63. PubMed ID: 22043770
[TBL] [Abstract][Full Text] [Related]
20. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
